No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Approval Alert: UCB’s Bimzelx® (Bimekizumab) Receives Korean Approval for Moderate to Severe Plaque Psoriasis
On 30 August 2024, Korea Biomedical Review reported that UCB’s Bimzelx® (bimekizumab) has received approval from the Korean Ministry of Food and Drug Safety as a treatment for moderate to severe adult plaque psoriasis. UCB says that Bimzelx® is the only treatment for...